Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial-Reference-Cited by-同舟云学术

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

Published:2020-06 Issue:6 Volume:7 Page:e490-e497
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Thanarajasingam Gita,Leonard John P,Witzig Thomas E,Habermann Thomas M,Blum Kristie A,Bartlett Nancy L,Flowers Christopher R,Pitcher Brandelyn N,Jung Sin-Ho,Atherton Pamela J,Tan Angelina,Novotny Paul J,Dueck Amylou C

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies;Thanarajasingam;Lancet Haematol,2018

2. The imperative for a new approach to toxicity analysis in oncology clinical trials;Thanarajasingam;J Natl Cancer Inst,2015

3. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0,2017

4. Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute workshop;Kluetz;Value Health,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. [Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework;Journal of Biopharmaceutical Statistics;2024-02-15

3. A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial;Cancer Control;2024-01

4. An Overview of Regression Models for Adverse Events Analysis;Drug Safety;2023-11-25

5. Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data;eJHaem;2023-08-25